Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19
- 1 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (10), 2977-2980
- https://doi.org/10.1093/jac/dkaa239
Abstract
Background: Remdesivir is a prodrug of the nucleoside analogue GS-441524 and is under evaluation for treatment of SARS-CoV-2-infected patients. Objectives: To evaluate the pharmacokinetics of remdesivir and GS-441524 in plasma, bronchoalveolar aspirate (BAS) and CSF in two critically ill COVID-19 patients. Methods: Remdesivir was administered at 200 mg loading dose on the first day followed by 12 days of 100 mg in two critically ill patients. Blood samples were collected immediately after (C0) and at 1 (C1) and 24 h (C24) after intravenous administration on day 3 until day 9. BAS samples were collected on Days 4, 7 and 9 from both patients while one CSF on Day 7 was obtained in one patient. Remdesivir and GS-441524 concentrations were measured in these samples using a validated UHPLC-MS/MS method. Results: We observed higher concentrations of remdesivir at C0 (6- to 7-fold higher than EC50 from in vitro studies) and a notable decay at C1. GS-441524 plasma concentrations reached a peak at C1 and persisted until the next administration. Higher concentrations of GS-441524 were observed in the patient with mild renal dysfunction. Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively. The CSF concentration found in Patient 2 was 25.7% with respect to plasma. GS-441524 levels in lung and CNS suggest compartmental differences in drug exposure. Conclusions: We report the first pharmacokinetic evaluation of remdesivir and GS-441524 in recovered COVID-19 patients. Further study of the pharmacokinetic profile of remdesivir, GS-441524 and the intracellular triphosphate form are required.Keywords
Funding Information
- Italian Ministry of Health
This publication has 15 references indexed in Scilit:
- Compassionate Use of Remdesivir for Patients with Severe Covid-19The New England Journal of Medicine, 2020
- Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus diseaseJournal of Antimicrobial Chemotherapy, 2020
- Arguments in favour of remdesivir for treating SARS-CoV-2 infectionsInternational Journal of Antimicrobial Agents, 2020
- First Case of 2019 Novel Coronavirus in the United StatesThe New England Journal of Medicine, 2020
- 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentationInternational Journal of Infectious Diseases, 2020
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nature Reviews Drug Discovery, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsThe New England Journal of Medicine, 2019
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- P-glycoprotein ABCB1: a major player in drug handling by mammals.JCI Insight, 2013